Revolax Sub-Q — Highest-Viscosity Monophasic HA Filler for Deep Sculpting

Revolax Sub-Q is Across Co.’s highest-viscosity variant — 24 mg/mL cross-linked HA + 0.3% lidocaine in a dense monophasic, polydensified structure with the highest G’ in the Revolax range. Engineered for deep subcutaneous and supraperiosteal placement: cheek augmentation, chin projection, jawline contouring, non-surgical rhinoplasty. 12-18 months durability with non-migratory cohesion.

Revolax Sub-Q with Lidocaine is manufactured by Across Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2009. The product is part of the Revolax dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE marked · GMP certified.

Revolax Sub-Q with Lidocaine contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Across Co. Ltd.’s Dense Monophasic BDDE Cross-Linking (Sub-Q Grade) technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Across Co. Ltd.’s clinical data, Revolax Sub-Q with Lidocaine delivers 12-18 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Deep subcutaneous placement typically delivers the longer end of the duration range.

Revolax Sub-Q with Lidocaine is engineered for deep subcutaneous · supraperiosteal placement. The standard recommended needle is 25G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Revolax Sub-Q with Lidocaine regulatory status: KFDA registered · CE marked · GMP certified. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Revolax Sub-Q with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Revolax Sub-Q with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Revolax Sub-Q with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Revolax Sub-Q is supplied with 25G needles (larger gauge than the 27G needles for Revolax Deep) because deep subcutaneous and supraperiosteal placement requires needle access to deeper tissue layers — and Sub-Q’s dense, polydensified monophasic gel requires more extrusion force than lighter Revolax variants. The 25G needle supports both adequate placement depth and smooth extrusion of the high-viscosity gel. Practitioners may substitute blunt cannulas of equivalent gauge for safer placement in highly vascular zones (cheek, jawline, nose).